The RGS2 gene, but not the OXTR gene, was also shown to be over-expressed in the majority of breast cancers, identifying the product of this gene, or the pathway(s) it regulates, as potentially significant therapeutic targets. The gene discussed is OXTR; the disease is breast carcinoma.